» Articles » PMID: 401541

The Role of Vasodilator Therapy in Heart Failure

Overview
Date 1977 Jan 1
PMID 401541
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

This article has attempted to summarize the current status of the therapeutic use of vasodilator drugs in acute and chronic heart failure. It is apparent from the increasing number of publications in this area that this alternative to more standard forms of therapy is likely to find a permanent and important place in the management of patients with heart disease. It should also be apparent that ideal drugs for the therapy of chronic heart failure are not yet available. Nevertheless, it is probable that such drugs will emerge and become at least as important as the routine use of digitalis in such patients.

Citing Articles

Myocardial Contractility: Historical and Contemporary Considerations.

Muir W, Hamlin R Front Physiol. 2020; 11:222.

PMID: 32296340 PMC: 7137917. DOI: 10.3389/fphys.2020.00222.


Levels of interleukin-6, superoxide dismutase and malondialdehyde in the lung tissue of a rat model of hypoxia-induced acute pulmonary edema.

Gao H, Tian Y, Wang W, Yao D, Zheng T, Meng Q Exp Ther Med. 2016; 11(3):993-997.

PMID: 26998026 PMC: 4774324. DOI: 10.3892/etm.2015.2962.


Internal medicine-epitomes of progress: vasodilator therapy for chronic congestive heart failure.

Parmley W, Chatterjee K West J Med. 1980; 133(3):235-6.

PMID: 18748680 PMC: 1272269.


Afterload reduction in the therapy of heart failure.

Fennell W Tex Heart Inst J. 1982; 9(1):61-9.

PMID: 15226814 PMC: 341474.


Mathematical model of cardiovascular mechanics for diagnostic analysis and treatment of heart failure: Part 2. Analysis of vasodilator therapy and planning of optimal drug therapy.

Tsuruta H, Sato T, Ikeda N Med Biol Eng Comput. 1994; 32(1):12-8.

PMID: 8182956 DOI: 10.1007/BF02512473.